Ex-Sebelius aide purges FDA office

Share this article:
FDA associate commissioner for external affairs Beth Martino, a former Kansas aide to HHS secretary Kathleen Sebelius, has conducted an unprecedented purge of senior specialists, all aged over 50, in her office and in the Press Office which she controls.
Sources confidential to me said the abrupt removals were made to make room for younger people closer to Martino's own age. “She's uncomfortable with people who know more than she does,” some of them said. Others alleged that the moves represent deeper politicization of the agency.
Three of the displaced staffers, Elaine Gansz Bobo, Dick Thompson,  and Ira Allen were offered the choice of being terminated as probationary hires for fabricated “incompetence” or resigning. Each had been told on their recruitment that, short of criminal behavior, “everybody survives the probationary period.”
As youth seems to trump experience in the Obama administration, similar purges are reportedly occurring at other HHS agencies, including CDC.
Martino told Bobo and Allen to immediately clean out their desks and they were then escorted off the premises. Thompson, a former TIME magazine Washington bureau science editor and high-level W.H.O. communications advisor, was told to find other work outside of FDA, but was allowed to stay until his 12-month probation expired on December 2.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?